1. Home
  2. CDLX vs BRNS Comparison

CDLX vs BRNS Comparison

Compare CDLX & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardlytics Inc.

CDLX

Cardlytics Inc.

HOLD

Current Price

$0.86

Market Cap

69.7M

Sector

Technology

ML Signal

HOLD

Logo Barinthus Biotherapeutics plc

BRNS

Barinthus Biotherapeutics plc

N/A

Current Price

$0.70

Market Cap

55.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CDLX
BRNS
Founded
2008
2016
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.7M
55.9M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
CDLX
BRNS
Price
$0.86
$0.70
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$2.25
$4.00
AVG Volume (30 Days)
863.9K
40.0K
Earning Date
03-11-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$251,175,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1766.46
52 Week Low
$0.85
$0.64
52 Week High
$3.62
$2.92

Technical Indicators

Market Signals
Indicator
CDLX
BRNS
Relative Strength Index (RSI) 29.90 45.43
Support Level $0.92 $0.70
Resistance Level $1.17 $0.74
Average True Range (ATR) 0.09 0.03
MACD -0.04 0.00
Stochastic Oscillator 0.07 36.50

Price Performance

Historical Comparison
CDLX
BRNS

About CDLX Cardlytics Inc.

Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.

Share on Social Networks: